Advancis Pharmaceutical Corp. is giving Amoxicillin Pulsys another chance. After the product, which combines the antibiotic amoxicillin with the company's once-a-day controlled-release Pulsys technology, missed in two pivotal trials earlier this year - and prompted a staff reduction and a dropped partnership - Advancis has rebounded with plans for another Phase III trial. (BioWorld Today)

Advancis Pharmaceutical Corp. is giving Amoxicillin Pulsys another chance. After the product, which combines the antibiotic amoxicillin with the company's once-a-day controlled-release Pulsys technology, missed in two pivotal trials earlier this year - and prompted a staff reduction and a dropped partnership - Advancis has rebounded with plans for another Phase III trial. (BioWorld Today)